Dual Nature of Relationship between Mycobacteria and Cancer

Fol, Marek; Koziński, Piotr; Kulesza, Jakub; Białecki, Piotr; Druszczyńska, Magdalena

doi:10.3390/ijms22158332

Cited by 17 publications

(16 citation statements)

References 123 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this meta-analysis, we reviewed their three treatment outcomes: the PFS and OS of LC patients with TB is longer than those without TB; the PFS and OS of LC patients with TB is shorter than those without TB; there was no statistically signi cant difference in OS and TTF between the two groups. This is consistent with the three main theories for the co-existence of lung cancer and TB: anti-cancer therapy can cause reactivation of TB; TB is a predisposing factor for lung cancer; or, it is random [30][31][32]. Some previous study has demonstrated that NSCLC patients with active TB show a better survival outcome; especially in squamous cell carcinoma [32][33][34].…”

Section: Discussionsupporting

confidence: 85%

Treatment strategies of patients with co-existing TB and LC: systematic reviews and meta-analysis

zhang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: Treatment strategies of patients with co-existing tuberculosis (TB) and lung cancer (LC) is still not conclusive, especially for advanced non-small cell lung cancer (NSCLC) patients with synchronous or not anti-TB and anti-cancer treatments. This systematic review and meta-analysis aim to assess treatment regimen and arrangement, the efficacy and safety of anti-cancer and anti-TB treatment in NSCLC patients with concomitant active TB.Methods: A Systematic and comprehensive search was performed in the following databases: PubMed, Embase, and Web of Science, in articles and abstracts published from 1929 to 2022. Six articles (involving 261 co-existing TB and LC cases and 8681 LC controls) met the inconclusive criteria. Review Manager version 5.4 (RevMan; Cochrane, Lindon, UK) software and Stata version 17.0 software were used for this statistical analysis.Results: The result of this meta-analysis demonstrates that LC patients with PTB appear to have had poor clinical response to treatment (log OR = 0.32, 95% confidence interval [CI] 0.03 - 0.61, p= 0.03, I2=8.68%). The results showed that lung cancer patients with TB infection had more adverse events (AEs) related to Immune-checkpoint inhibition (ICI), chemotherapy, or target drug treatment (log RR=0.11, 95% CI=0.001–0.02, p= 0.04, I2=38.84%). However, after removing AEs related to ICI treatment, other AEs of any grade were similar in patients with or without PTB treated with chemotherapy or target drug (log RR=0.07, 95% CI=-0.04–0.18, p=0.64, I2=0.00%). Timing to anti-cancer therapy: for 39.0% (102/261) of patients, at least 1-4 weeks after the start of anti-TB therapy; for 3.4% (9/261) of patients, at 2 weeks before the start of anti-TB treatment; for 14.6% (38/261) of patients, at received the anti-TB treatment at the same time.Conclusion: The present meta-analysis demonstrated that LC patients with TB have a poorer treatment response than those without TB; LC patients with TB receiving first-line chemotherapy or targeted therapy and anti-TB treatment at least 1-4 weeks after the start of anti-TB treatment or at the same time will not increase the incidence of AEs.

show abstract

Section: Discussionsupporting

confidence: 85%

Treatment strategies of patients with co-existing TB and LC: systematic reviews and meta-analysis

zhang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…NCFB represents a complex heterogeneous condition, and each underlining cause (COPD, infections, autoimmune diseases, genetic conditions, etc.) is known to impact differently on cancer risk [ 44 , 45 , 46 , 47 ]. To date, the chronic inflammatory process in COPD has been extensively analyzed, and different phenotypes associated with specific cytokine patterns favoring the tumor microenvironment have been identified [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Do Patients with Bronchiectasis Have an Increased Risk of Developing Lung Cancer? A Systematic Review

Castaldo¹,

Fantin²,

Manera

et al. 2023

Life

View full text Add to dashboard Cite

Background: Initial evidence supports the hypothesis that patients with non-cystic fibrosis bronchiectasis (NCFB) have a higher risk of lung cancer. We systematically reviewed the available literature to define the characteristics of lung malignancies in patients with bronchiectasis and the characteristics of patients who develop bronchiectasis-associated lung cancer. Method: This study was performed based on the PRISMA guidelines. The review protocol was registered in PROSPERO. Results: The frequency rates of lung cancer in patients with NCFB ranged from 0.93% to 8.0%. The incidence rate was 3.96. Cancer more frequently occurred in the elderly and males. Three studies found an overall higher risk of developing lung cancer in the NCFB population compared to the non-bronchiectasis one, and adenocarcinoma was the most frequently reported histological type. The effect of the co-existence of NCFB and COPD was unclear. Conclusions: NCFB is associated with a higher risk of developing lung cancer than individuals without NCFB. This risk is higher for males, the elderly, and smokers, whereas concomitant COPD’s effect is unclear.

show abstract

“…Zn 2+ is an essential but toxic microelement in high concentrations and can serve as an antimicrobial strategy for Mycobacterium [ 43 , 44 ], which can provoke chronic inflammation related to cancer pathogenesis [ 45 ]. Meanwhile, the P1B-type ATPase CtpG (Rv3270) was recently identified as a Zn 2+ efflux transporter via the CmtR-CtpG-Zn 2+ regulatory pathway that enhances mycobacterial resistance to Zn 2+ toxicity because the accumulation of Zn 2+ can contribute to ROS detoxification in mycobacterial cells [ 46 ].…”

Section: Metal Ions Participate In Innate and Adaptive Immune Activat...mentioning

confidence: 99%

Metal ions and nanometallic materials in antitumor immunity: Function, application, and perspective

Shen

Fang

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

The slightest change in the extra/intracellular concentration of metal ions results in amplified effects by signaling cascades that regulate both cell fate within the tumor microenvironment and immune status, which influences the network of antitumor immunity through various pathways. Based on the fact that metal ions influence the fate of cancer cells and participate in both innate and adaptive immunity, they are widely applied in antitumor therapy as immune modulators. Moreover, nanomedicine possesses the advantage of precise delivery and responsive release, which can perfectly remedy the drawbacks of metal ions, such as low target selectivity and systematic toxicity, thus providing an ideal platform for metal ion application in cancer treatment. Emerging evidence has shown that immunotherapy applied with nanometallic materials may significantly enhance therapeutic efficacy. Here, we focus on the physiopathology of metal ions in tumorigenesis and discuss several breakthroughs regarding the use of nanometallic materials in antitumor immunotherapeutics. These findings demonstrate the prominence of metal ion-based nanomedicine in cancer therapy and prophylaxis, providing many new ideas for basic immunity research and clinical application. Consequently, we provide innovative insights into the comprehensive understanding of the application of metal ions combined with nanomedicine in cancer immunotherapy in the past few years. Graphical Abstract

show abstract

Dual Nature of Relationship between Mycobacteria and Cancer

Cited by 17 publications

References 123 publications

Treatment strategies of patients with co-existing TB and LC: systematic reviews and meta-analysis

Treatment strategies of patients with co-existing TB and LC: systematic reviews and meta-analysis

Do Patients with Bronchiectasis Have an Increased Risk of Developing Lung Cancer? A Systematic Review

Metal ions and nanometallic materials in antitumor immunity: Function, application, and perspective

Contact Info

Product

Resources

About